Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Required: NPM1 mutation

Normal karyotype with mutated NPM1 and wild type FLT-ITD

Required: FLT3 wild-type

Normal karyotype with mutated NPM1 and wild type FLT-ITD

Required: CEBPA double mutated

Normal karyotype with double mutated CEBPA

Required: MLL rearrangement

other MLL rearrangements

Required: IKZF1 mutation

IKZF1

Excluded: KIT mutation

t(8,21) without cKIT mutation; inv(16) or t(16;16) without cKIT mutation

Must have received: tyrosine kinase inhibitor — Chronic Myelogenous Leukemia, first chronic phase (CP1)

To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.

Must have received: initial therapy — Plasma Cell Leukemia

Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission

Must have received: initial therapy — Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia

Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.

Cannot have received: myeloablative transplant

Exception: if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant

if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant